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Abstract
Modification of serine and threonine residues in proteins by O-linked b-N-acetylgulcosamine (O-GlcNAc) glycosylation is a
feature of many cellular responses to the nutritional state and to stress. O-GlcNAc modification is reversibly regulated by O-
linked b-N-acetylgulcosamine transferase (OGT) and b-D-N-acetylgulcosaminase (O-GlcNAcase). O-GlcNAc modification of
proteins is dependent on the concentration of uridine 59-diphospho-N-acetylgulcosamine (UDP-GlcNAc), which is a
substrate of OGT and is synthesized via the hexosamine biosynthetic pathway. Immunoblot analysis using the O-GlcNAc-
specific antibody CTD110.6 has indicated that glucose deprivation increases protein O-GlcNAcylation in some cancer cells.
The mechanism of this paradoxical phenomenon has remained unclear. Here we show that the increased glycosylation
induced by glucose deprivation and detected by CTD110.6 antibodies is actually modification by N-GlcNAc2, rather than by
O-GlcNAc. We found that this induced glycosylation was not regulated by OGT and O-GlcNAcase, unlike typical
O-GlcNAcylation, and it was inhibited by treatment with tunicamycin, an N-glycosylation inhibitor. Proteomics analysis
showed that proteins modified by this induced glycosylation were N-GlcNAc2-modified glycoproteins. Furthermore,
CTD110.6 antibodies reacted with N-GlcNAc2-modified glycoproteins produced by a yeast strain with a ts-mutant of ALG1
that could not add a mannose residue to dolichol-PP-GlcNAc2. Our results demonstrated that N-GlcNAc2-modified
glycoproteins were induced under glucose deprivation and that they cross-reacted with the O-GlcNAc-specific antibody
CTD110.6. We therefore propose that the glycosylation status of proteins previously classified as O-GlcNAc-modified
proteins according to their reactivity with CTD110.6 antibodies must be re-examined. We also suggest that the repression of
mature N-linked glycoproteins due to increased levels of N-GlcNAc2-modifed proteins is a newly recognized pathway for
effective use of sugar under stress and deprivation conditions. Further research is needed to clarify the physiological and
pathological roles of N-GlcNAc2-modifed proteins.
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Introduction
We previously screened proteins as tumor markers for
bladder cancer by proteomic analysis of cancerous and health
tissues and identified some proteins, calreticulin et al, as
markers [1–3]. We next attempted to screen for proteins that
were key molecules in metastasis and invasiveness by proteomic
analysis of bladder carcinoma cell line T24 cells. The T24 cells
were modified by introduction of a tumor suppressor gene,
after which they lost their invasiveness activity [4]. However,
we could not find protein expression patterns that differed
between these cell types. Therefore, we devised two improve-
ments: application of focused proteomics and use of cells under
stress conditions. Application of focused proteomics involves
screening of minor key proteins. The usual culture medium has
very rich nutrients and does not reflect to the in vivo
environment. We examined changes in the O-linked b-
N-acetylgulcosamine (O-GlcNAc)-glycosylated proteins in T24
cells under glucose deprivation. O-GlcNAc-modification of
proteins is a feature of many cellular responses to the
nutritional state and to stress [5–7]. O-GlcNAc is attached to
the protein backbone by enzymatic addition of the N-
acetylgulcosamine (GlcNAc) moiety of uridine 59-diphospho
(UDP)-GlcNAc to the hydroxyl oxygen of serines or threonines
by the O-linked b-N-acetylgulcosamine transferase (OGT). O-
GlcNAc glycosylated proteins can be reversiblely deglycosy-
lated by b-D-N-acetylgulcosaminase (O-GlcNAcase). These
reversible O-GlcNAc glycosylations are distinct from stable,
complex N-linked glycosylations of membrane or secreted
proteins, which takes place in the lumen of the endoplasmic
reticulum and in the Golgi apparatus. O-GlcNAc modification
of proteins is dependent on the concentration of UDP-GlcNAc,
which is synthesized by the hexosamine biosynthetic pathway
(HBP, Figure 1a) [8]. Glucose deprivation induced increased
expression of proteins that reacted with the O-GlcNAc specific
antibody CTD110.6, despite the decreased concentration of
UDP-GlcNAc. These paradoxical phenomena were previously
reported for the human hepatocellular carcinoma cell line
HepG2 cells, mouse neuroblastoma cell line Neuro-2a cells,
and some cancerous cells [9–12]. In this study, we attempted to
identify and characterize the proteins in T24 cells that reacted
with the O-GlcNAc-specific antibody CTD110.6 under glucose
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fied glycoproteins were induced under glucose deprivation and
that they cross-reacted with the O-GlcNAc-specific antibody
CTD110.6.
Results
When T24 human bladder cancer cells were subjected to
glucose deprivation, the expression of proteins detected by the O-
GlcNAc specific antibody CTD110.6 increased more than 5-fold
(Figure 1b), as previously reported [9–12]. The expression of basal
proteins that reacted with CTD110.6 antibodies in high-glucose
medium (25 mM glucose) decreased 3 h after glucose deprivation
initiated by incubation of the cells in medium with 0 mM glucose,
but the signals returned to the original basal levels 6 h after
glucose deprivation was initiated. Expression of the newly induced
proteins, which reacted with CTD110.6 antibodies only under
glucose deprivation conditions, detected at the 6 h time point,
continued to increase until 24 h after the treatment, become major
part of proteins that reacted with CTD110.6 antibodies 24 h after
the treatment (Figure 1b). These results suggested that two kinds of
proteins, the basal proteins and the induced proteins, were
produced under glucose deprivation conditions.
We next examined the effects of treating the cells with siRNA
specific for OGT and with PUGNAc, an inhibitor of O-GlcNAcase,
on expression of proteins that reacted with CTD110.6 antibodies
under glucose deprivation (Figure 1c). In the high-glucose
medium, expression of the basal proteins increased following
treatment with PUGNAc, and the signal clearly decreased
following knockdown of OGT with siRNA, as expected. When
the cells were incubated in glucose deprivation medium, the
responses of basal protein expression levels to treatment with
PUGNAc and knockdown with siRNA were similar in the high-
glucose medium. However, the induced protein expression levels
did not increase following treatment with PUGNAc and their
levels did not decrease following siRNA knockdown, unlike the
basal proteins. The induced proteins also prevented the reactivity
with CTD110.6 antibodies upon addition of 10 mM GlcNAc, like
the basal proteins (Figure S1), but they did not react with another
O-GlcNAc specific antibody, RL-2, unlike the basal proteins
(Figure S2). Then the induced proteins did not react clearly with
the Click-It O-GlcNAc detection system, though the basal proteins
reacted strongly with this system (Figure S3). These results
suggested that the induced proteins differed from the typical O-
GlcNAc-modified proteins, which included the basal proteins.
The induced proteins were next analyzed by LC/MS/MS. Six
proteins were identified, as shown in Figure 2a and Table S1. Two
of the six proteins, Nup88 and HSP70, are common O-GlcNAc-
modified proteins [5], and they may constitute some of the basal
proteins. The other four proteins (ORP150, Laminin b3, Mac2BP,
and CD98HC) are glycoproteins with N-linked sugars, and they
had not been identified previously as O-GlcNAc-modified proteins.
We carried out the validations of the four proteins identified by
their reactivity with CTD110.6 antibodies following glucose
deprivation of T24 cells by immunoblot (Figure 2b) and
immunoprecipitation analysis (Figure 2c). Immunoblot analysis
using anti-ORP150 antibodies showed a decrease in the
glycosylated form, GRP170, in the high-glucose medium, while
levels of the lower molecular weight form corresponding to non-
glycosylated ORP150 increased under glucose deprivation.
Immunoblot analysis with anti-Laminin b3 antibodies showed
that Laminin b3 also shifted to the lower molecular weight form in
glucose deprivation medium. The bands seen for the lower
molecular weight forms of ORP150 and Laminin b3 corresponded
to the 120 kDa bands previously identified as proteins based on
their reaction with CTD110.6 antibodies under glucose depriva-
tion. Immunoblot analysis with anti-CD98HC antibodies showed
that glucose deprivation caused a decrease in the70,100 kDa.
Glycosylated form of CD98HC, while an approximately 55 kDa
low molecular weight form was induced by glucose deprivation.
Immunoblot analysis with anti-Mac2BP antibodies showed that
the 70 and 90 kDa. Glycosylated forms of Mac2BP decreased and
the approximately 55 kDa low molecular weight form was induced
by glucose deprivation. The bands corresponding to the lower
molecular weight forms of CD98HC and Mac2BP also matched
the 55 kDa bands previously identified as induced proteins based
on their reaction with CTD110.6 antibodies under glucose
deprivation. Immunoblot analysis following the time course of
glucose deprivation responses showed that the levels of the lower
molecular weight forms of the four proteins were clearly increased
at 6 h after the treatment, i.e. at the same time that an increase
was previously noted for proteins identified by their reaction with
CTD110.6 antibodies (Figure 1b). The immunoprecipitation
analysis showed that CTD110.6 antibodies reacted with all four
of the lower molecular weight forms that were immunoprecipitat-
ed by their specific antibodies, respectively, but not with the
mature glycosylated forms. Knockdown of ORP150 with siRNA
specifically decreased the expression of the 120 kDa ORP150
protein, which was previously identified using the CTD110.6
antibodies under glucose deprivation (Figure S4). These results
demonstrated that the lower molecular weight forms of ORP150,
Laminin b3, CD98HC, and Mac2BP were induced by glucose
deprivation, and that CTD110.6 antibodies also reacted with them
under glucose deprivation.
We next examined the effects of tunicamycin, which inhibits N-
glycosylation, on expression of the induced proteins (Figure 3a).
Tunicamycin treatment increased the expression of basal proteins
in high-glucose medium with PUGNAc, as previously described
[13]. These results were reasonable, as the pool of UDP-GlcNAc
was increased by the inhibition of tunicamycin, so more was
available for O-GlcNAcylation. When the cells were incubated in
glucose deprivation medium, tunicamycin treatment increased
expression of the basal proteins, similar to the response in the high
glucose conditions with PUGNAc. However, expression of the
induced proteins disappeared following tunicamycin treatment,
unlike the basal proteins. ORP150, Laminin b3, CD98HC, and
Mac2BP were detected as their naked forms following tunicamycin
treatment in both high glucose medium and in glucose deprivation
Figure 1. The glycosylation induced under glucose deprivation was not regulated by OGT and O-GlcNAcase. a, The hexosamine
biosynthetic pathway and O-GlcNAcylation. b, An immunoblot showing CTD110.6 antibody reaction over the time course during incubation of T24
cells in glucose deprivation medium (0 mM glucose). An anti-a-tubulin antibody was used as an internal control. The right panel shows a quantitative
analysis of reactivity with the CTD110.6 antibody, normalized to the anti-a-tubulin antibody signal of the time 0 samples. Error bars represent
standard error from three experiments. * represents p,0.001. c, The effects of treatment with siRNA against OGT and with PUGNAc on expression
levels of proteins that reacted with CTD110.6 antibodies under glucose deprivation. The left panel shows an immunoblot for CTD110.6, anti-OGT, and
anti-a-tubulin antibodies. The right panel shows a quantitative analysis of reactivity with the CTD110.6 antibody and with an anti-OGT antibody,
normalized to the anti-a-tubulin signal for untreated samples in high-glucose medium. Error bars represent standard error from three experiments.
* represents p,0.05.
doi:10.1371/journal.pone.0018959.g001
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detected by CTD110.6 antibodies following glucose deprivation,
were slightly higher than the bands produced following tunica-
mycin treatment. These tunicamycin effects were observed also in
HepG2 (Figure S5) cells and Neuro-2a cells (Figure S6). When the
supernatants derived from T24 cells incubated in glucose
deprivation medium were treated with Peptide-N-glycosidase F
(PNGaseF), which removes all N-glycans from peptides, the bands
corresponding to the induced proteins disappeared, although the
bands corresponding to the basal proteins did not change
(Figure 3c). These results suggested that the induced proteins
contained N-linked sugars.
The induced proteins were analyzed by LC/MS/MS in order
to further characterize the sugar residues. FLAG-tagged Mac2BP
proteins were over-expressed in T24 and 293T cells (Figure 3d). In
both cases, these proteins reacted with CTD110.6 antibodies
under glucose deprivation, suggesting that they had been modified
with sugar residues. FLAG-tagged Mac2BP proteins that were
over-expressed in 293T cells were concentrated by a-FLAG beads
and analyzed by LC/MS/MS, and peptides containing residues
modified with GlcNAc2 were found (Figure 3e). The Mac2BP
protein sequence contains seven potential N-linked glycosylation
sites (N-X-S/T), and N-GlcNAc2 modification was found at five of
these sites (Table S2). This result suggested that CTD110.6
antibodies reacted with N-GlcNAc2-modifed proteins induced by
glucose deprivation.
The existence of N-GlcNAc2-modifed proteins has been
reported in the yeast ts-mutant K57-6C [14]. This mutant could
not add a mannose residue to dolichol-PP-GlcNAc2, as indicated
by a loss of ALG1 activity and secretion of N-GlcNAc2-modifed
exoglucanase following a temperature shift from 25 to 37uC. N-
GlcNAc2-modifed exoglucanase protein was detected in the yeast
culture medium at 37uC by CTD110.6 antibodies (Figure 4a).
This signal decreased following tumicamycin treatment of the
Figure 2. The identification and validation of proteins induced under glucose deprivation that reacted with CTD110.6 antibodies. a,
The induced proteins were detected by CTD110.6 antibody. The . marks indicate the area excised for LC/MS/MS. The identified proteins are
indicated. b, An immunoblot showing the four proteins induced by glucose deprivation. The incubation times for in high-glucose medium (25 mM
glucose) or in glucose deprivation medium (0 mM glucose) are indicated. An anti-a-tubulin antibody was used as an internal control. c, Immunoblots
showing immunoprecipitation samples of the four induced proteins.
doi:10.1371/journal.pone.0018959.g002
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the medium supernatant. These results suggested that CTD110.6
antibodies reacted with the N-GlcNAc2-modifed proteins that were
induced by the loss of ALG1 activity.
In yeast, the expression of ALG1 is decreased when the carbon
source is depleted [15]. However, in T24 cells, the ALG1 band
shifted to a slightly higher molecular weight and this shifted band
appeared 3 h after glucose deprivation, before the production of
N-GlcNAc2-modifed proteins was observed (Figure 4b). This
suggested that the ALG1 enzyme activity may have been lost. We
examined the effects of siRNA specific for ALG1on the production
of N-GlcNAc2-modifed proteins (Figure 4c). Under high-glucose
medium conditions, the expression of proteins reacted with the O-
GlcNAc specific antibody CTD110.6 and the expression of N-
GlcNAc2-modifed ORP150 hardly increased. However, under
glucose deprivation, the expression of proteins reacted with the O-
GlcNAc specific antibody CTD110.6 and the expression of N-
GlcNAc2-modifed ORP150 some increased. This result suggested
that inhibition of ALG1 induced the production of N-GlcNAc2-
modifed proteins under glucose deprivation. The slight effects of
siRNA may have been due to a loss of ALG1 enzyme activity
caused by modification of ALG1 under glucose deprivation. The
partial knock down by siRNA of ALG1 in the high-glucose
medium may have caused incomplete inhibition of N-GlcNAc2-
modifed protein production.
Discussion
The experiments described here clearly indicate that N-
GlcNAc2-modifed proteins induced under glucose deprivation
cross-reacted with the antibody CTD110.6, indicating that this
antibody is not actually specific for O-GlcNAc-modified proteins.
A schematic summary of all of the experimental results and the
hypothesis is presented in Figure 4d. Previous reports have
demonstrated the specificity of CTD110.6 antibodies for O-linked
derivatives, but their possible specificity for N-linked derivatives
containing N-GlcNAc2 was not evaluated [16]. N-GlcNAc may
mimic S/T and thus ‘deceive’ CTD110.6 antibodies as it attaches
the second GlcNAc with an O-type linkage. Previous paradoxical
reports that glucose deprivation increased protein O-GlcNAcyla-
tion in some cancer cells may now be explained by the present
study. Our results (Figure 3a, 3b, and Figure S5, S6) suggest that
N-GlcNAc2-modifed proteins, with which CTD110.6 antibodies
reacted under glucose deprivation, are produced by T24 cells as
well as by some cancerous cells. Therefore, we proposed that the
proteins previously classified as O-GlcNAc-modified proteins
according to their reactivity with CTD110.6 antibodies must be
re-examined to determine whether they are actually O-GlcNAc- or
N-GlcNAc2-modifed proteins. The O-GlcNAc specific antibody,
RL-2, is not N-GlcNAc2-modifed proteins (Figure S2), so RL-2
antibodies may be more specific for O-GlcNAc-modifed proteins
than CTD110.6 antibodies. Our work has demonstrated that
production of N-GlcNAc2-modifed proteins will induced by
inhibiting the addition of a mannose residue to dolichol-PP-
GlcNAc2 using the yeast Alg1 ts-mutant. In nature, Plasmodium
falicparum lacks the Alg1gene and produces N-GlcNAc2-modifed
proteins [17]. Congenital Disorders of Glycosylation (CDG) is N-
glycosylation disorder induced by mutations of genes in dolichol-
linked oligosaccharide biosynthetic pathway [18]. Type Ik patients
had mutations of the Alg1 gene and accumulated dolichol-PP-
GlcNAc2 [19]. This suggested that these patients produced N-
GlcNAc2-modifed proteins, similar to the phenomenon observed
for the yeast Alg1 ts-mutant. Type Ia, the largest group of CDG
patients, had mutations of the Phosphomannomutase 2 (PMM2)
gene, which encodes a key enzyme of GDP-mannose synthesis
[18]. GDP-mannose is a substrate for ALG1, so inhibition of
PMM2 enzyme activity will accumulate dolichol-PP-GlcNAc2 and
produce N-GlcNAc2-modifed proteins. Glucose deprivation will
inhibit dolichol-linked oligosaccharide biosynthesis like the
defection of CDG patients. Our digital expression analysis for
the time course of glucose deprivation by next-generation
sequencing showed that the expression level of Serum and
Glucocorticoid-regulated kinase (Sgk1), which inhibits PMM2
enzyme activity [20], was up-regulated tenfold by glucose
deprivation (data in preparation). This suggests that the synthesis
of GDP-mannose was inhibited by glucose deprivation. It is likely
that inactivation of both ALG1 and GDP-mannose synthesis was
induced under glucose deprivation and that this contributed to the
production of N-GlcNAc2-modifed proteins. Therefore, N-
GlcNAc2-modifed proteins may not be produced in high-glucose
medium only through inhibition by ALG1 siRNA. The addition of
glucosamine under low glucose conditions induced the typical O-
GlcNAc-modified proteins but not N-GlcNAc2-modifed proteins
[9]. An adequate supply of sugars such as glucose and glucosamine
will overcome inhibition of GDP-mannose synthesis and will not
induce the production of N-GlcNAc2-modified proteins. The
production of N-GlcNAc2-modified proteins in T24 and some
cancer cell line cells may require the deprivation of sugar. We
suggest that the repression of mature N-linked glycoproteins due to
increased levels of N-GlcNAc2-modifed proteins is a newly
recognized pathway for effective use of sugar under stress and
deprivation conditions. Further research is needed to clarify the
physiological and pathological roles of N-GlcNAc2-modifed
proteins, and the results of these studies will be applicable across
a wide range of fields.
Materials and Methods
Cell lines and cell culture conditions
The human bladder cancer cell line, T24 [21] and human
embryonic kidney cell line, 293T [22] were usually cultured in the
high-glucose version of Dulbecco’s modified Eagle’s medium
(DMEM, Nacalai Tesque, Kyoto, Japan), which contained
25 mM glucose and 1 mM sodium pyruvate, supplemented with
10% fetal calf serum (FCS), penicillin (100 U/ml), and strepto-
mycin (100 mg/ml) at 37uC in a humidified 5% CO2 atmosphere.
In the experimental culture, cells were seeded in high-glucose
medium and then treated with or without transfection of plasmid
DNA or small interference RNA (siRNA) at day 1. The culture
medium was then replaced on day 2 with fresh high-glucose
Figure 3. The proteins induced by glucose deprivation were modified with N-GlcNAc2.a , The effects of tunicamycin treatment on the
expression of proteins that reacted with CTD110.6 antibodies under glucose deprivation. The left panel shows immunoblots for CTD110.6 and anti-a-
tubulin antibodies. The right panel shows a quantitative analysis of reactivity with the CTD110.6 antibody and with an anti-OGT antibody, normalized
to the anti-a-tubulin signal for untreated samples in high-glucose medium. Error bars represent standard error from three experiments. * represents
p,0.01. b, An immunoblot showing effects of tunicamycin treatment on the four induced proteins. c, An immunoblot showing the effects of the
treatment of PNGase F treatment on the supernatants from T24 cells that were cultured in glucose deprivation medium. d, An immunoblot showing
the effects of Mac2BP over-expression in T24 cells and 293T cells. e, The LC/MS/MS spectrum analysis for the peptides derived from over-expressed
Mac2BP protein.
doi:10.1371/journal.pone.0018959.g003
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which was depleted of glucose and sodium pyruvate (0 mM
glucose, Invitrogen, Carlsbad, CA), and supernatants were
collected on day 3. The treatments with PUGNAc (100 mM) and
tunicamycin (2 mg/ml) were carried out when the medium was
replaced on day 2. Saccharomyces cerevisiae strain K57-6C (MATa,
alg1-1, ura3-52) was purchased from ATTC. Yeast cells were
maintained in YEPD medium. For the production of external
exoglucanase, cells were grown in liquid minimal medium
supplemented with uracil plus adenine at 26 and 37uCa s
described [14].
Plasmids and transfection
We amplified a human gene for Mac2BP from T24 cells by PCR,
using a pair of human Mac2BP-specific primers: MACS1 (59-
AGGCACGGCCATGACCCCTC-39, nucleotide 170–189) and
MACA2 (59-GTCCACACCTGAGGAGTTGGTC-39, nucleotide
1914–1893), which corresponded to the nucleotide sequence of the
human Mac2BP gene (ENST00000262776). The amplified PCR
fragments were cloned into the EcoRI/blunt site of the pCR3.1-
FLAG-CT expression vector [23]. The pCR3.1-FLAG-CT was
constructed by a synthesized FLAG tag cassette introduced into the
EcoRI-PstI/blunt sites of the pCR3.1 expression vector, and a stop
codon at the C-terminus of the FLAG tag sequence was introduced
by this joining. DNA sequencing of the PCR products was
performed by the dideoxy chain termination method using an
ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA). Plasmids were prepared using PureLink HiPure
Plasmid DNA Purification Kits (Invitrogen). Transfection of
plasmids was carried out in 90-mm dishes using Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s protocol.
siRNA
siRNA targeting human OGT (L-019111-00-0005) and scram-
bled control (D-001810-01-05) RNA duplexes were purchased
from Dharmacon, Inc. (Lafayette, CO). siRNAs targeting human
Alg1 (NM_019109_stealth_372) RNA duplexes were purchased
from Invitrogen. Cells were transfected with RNA duplexes using
Lipofectamine RNAiMAX reagents (Invitrogen) following the
manufacturer’s protocol.
Antibodies
Anti-O-GlcNAc (#MMS-248R, CTD110.6) IgM monoclonal
antibody was purchased from Covance (Berkeley, CA). Anti-
CD98HC (#9160, H-300), anti-OGT (#32921, H-300), and
anti-Laminin b-3 (#20775, H-300) antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
Mac2BP (#710281-1-AP) and anti-ALG1 (#12872-1-AP)
antibodies were purchased from Protein Tech Group (Chicago,
Ill.). Anti-ORP150 antibody (#10301, monoclonal) was pur-
chased from Immuno-Biological Laboratories (Takasaki, Ja-
pan). Anti-a-tubulin (#T9026, DM1A) and anti-FLAG
(#F3165, M2) monoclonal antibodies were purchased from
Sigma-Aldrich (St. Louis, MO).
Immunoblotting
Cells were lysed in Laemmli-SDS buffer, subjected to SDS-
polyacrylamide gel electrophoresis, and electro-transferred to
membrane filters (Immuno-Blot PVDF membranes, Bio-Rad
Laboratories, Richmond, CA). The filters were incubated with a
primary antibody in TBS-T (10 mM Tris-HCl, pH 7.6, 150 mM
sodium chloride, 0.1% Tween20) containing 2% bovine serum
albumin (BSA) overnight and incubated for 1 hour in horseradish
peroxidase-conjugated anti-mouse, anti-rabbit (GE Healthcare,
Buckinghamshire, UK), or anti-mouse IgM (Sigma-Aldrich)
diluted 1:5,000 in TBS-T containing 2% BSA. Immunoreactivity
was detected using the ECL system (GE Healthcare) with
LAS4000 (Fujifilm, Tokyo, Japan) and quantified with Multi
gauge (Fujifilm), using an anti-a-tubulin antibody as an internal
control. All quantification analyses were performed in triplicate.
Immunoprecipitation
Cells were lysed in Brij lysis buffer containing 20 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1% Brij 98 (Sigma-Aldrich), a protease
inhibitor cocktail (Nakalai Tesque), O-GlcNAcase inhibiter, O-(2-
acetamide-2-deoxy-D-glucopyranosilidene)amino N-phenylcarba-
mate (PUGNAc; Toronto Research Chemicals, Ontario, Canada),
and a phosphatase inhibitor cocktail (Sigma-Aldrich) and were
centrifuged for 30 minutes at 10,0006ga t4 uC. The supernatant
was incubated with the specific antibody at 4uC for 1 hour. The
immunocomplexes were bound to protein-G sepharose for 1 hour
at 4uC and washed five times with TBS-T. The proteins bound to
the resin were eluted by adding 26Laemmli-SDS sample buffer,
to a final concentration of 62.5 mM Tris-HCl (pH 6.8), 10%
glycerol, 5% 2-mercaptoethanol, 2% sodium dodecyl sulfate
(SDS), and 0.01% bromophenol blue, and the samples were
boiled for 5 minutes. After centrifugation at 10,0006g for
2 minutes, the supernatants were analyzed by immunoblotting.
Identification of the proteins by LC/MS/MS analyses
T24 cells were lysed in Brij lysis buffer and centrifuged for
30 minutes at 10,0006ga t4 uC. The supernatants were incubated
with the anti-O-GlcNAc CTD110.6 IgM monoclonal antibody at
4uC for 1 hour and for an additional 1 hour with added anti-
mouse IgM antibody. The immunocomplexes were bound to
protein-G sepharose for 1 hour at 4uC and washed five times with
TBS-T. The proteins bound to the agarose were eluted by adding
26Laemmli-SDS sample buffer and subjected to SDS-polyacryl-
amide gel electrophoresis. To identify the CTD110.6 antibody-
reacted bands, the electro-transferred membrane filter was both
stained with DeepPurple (GE Helthcare) and immunoblotted with
CTD110.6 antibody. Each identified band, which was stained with
SproRuby in another gel, was digested in the gel by modified
trypsin (Promega, Madison, WI) as described previously [24]. The
extracted samples were analyzed using the LC/MS/MS system
with Paradigm MS4 (AMR, Tokyo, Japan), Finnigan LCQ
Advantage (Thermo Fisher Scientific, Waltman, MA), and
Bioworks analyzer soft (Thermo Fisher Scientific). FLAG-tagged
Mac2BP proteins in 293T cells were concentrated with anti-FLAG
affinity agarose (Sigma-Aldrich) for LC/MS/MS analysis.
Figure 4. N-GlcNAc2 produced by repression of Alg1 cross-reacts with CTD110.6 antibodies. a, An immunoblot showing CTD110.6
antibody of Alg1-ts-mutant yeast culture medium. b, An immunoblot showing anti-Alg1 antibody reaction over the time course during incubation of
T24 cells in glucose deprivation medium (0 mM glucose). An anti-a-tubulin antibody was used as an internal control. c, The effects of treatment with
siRNA specific for Alg1 on the expression of proteins that reacted with CTD110.6 antibodies under glucose deprivation. The left panel shows an
immunoblot for CTD110.6, anti-ALG1, anti-ORP150 and anti-a-tubulin antibodies. The right panel shows a quantitative analysis of reactivity with the
CTD110.6 antibody and with ALG1 in three experiments, all normalized to the anti-a-tubulin signal for untreated samples in high-glucose medium.
d, A schematic summary of all of the experimental results and the hypothesis.
doi:10.1371/journal.pone.0018959.g004
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T24 cells were lysed in the solubilization buffer containing 1%
SDS, 20 mM sodium phosphate (pH 6.0), 10 mM EDTA, 1% 2-
mercaptoethanol, heated for 2 minutes, diluted using a dilution
buffer containing 0.5% NP40, 50 mM sodium phosphate
(pH 6.0), 10 mM EDTA, 1% 2-mercaptoethanol, and then
treated with 1/15 U PNGase F for 5 hours. The supernatants of
the yeast cell cultures were concentrated by Microcon YM-10
(Millipore, Billerica, MA) and treated as described above.
Statistics
Results of experiments are represented as mean 6 S.E. Each
mean represents data from at least three independent experiments.
The Student’s t test (two-tail) was used to compare differences
between groups.
Supporting Information
Figure S1 The effects of the treatment with 10m-
MGlcNAc on the expression of proteins that reacted
with CTD110.6 antibodies under glucose deprivation.
The left panel shows an immunoblot for CTD110.6 and anti-a-
tubulin antibodies. The right panel shows an immunoblot for
CTD110.6 with 10mMGlcNAc and anti-a-tubulin antibodies.
(TIF)
Figure S2 The reactivity of the induced proteins, that
reacted with CTD110.6 antibodies under glucose depri-
vation, with O-GlcNAc-specific antibody RL2. The left
panel shows an immunoblot for RL2 (Santa Cruz Biotechnology)
and anti-a-tubulin antibodies. The right panel shows a quantita-
tive analysis of reactivity with the RL2 antibody, normalized to
the anti-a-tubulin signal for untreated samples in high-glucose
medium. Error bars represent standard error from three
experiments.
(TIF)
Figure S3 The reactivity of the induced proteins, that
reacted with CTD110.6 antibodies under glucose depri-
vation, with Click-iT O-GlcNAc Enzymatic labeling
system. Cell extract collected from each one day culture of
T24 cell by solubilizing with Brij lysis buffer. O-GlcNAc-modified
proteins were labeled with Click-iT O-GlcNAc Enzymatic labeling
system (Invitrogen) and Click-iT biotin Glycoprotein Detection
Kit (Invitrogen) according to the manufacture’s protocol. The left
panel shows an immunoblot for CTD110.6 antibodies for cell
extract. The right panel shows an immunoblot for anti-biotin
antibodies (Cell Signaling Technology) for biotin-labeled samples.
(TIF)
Figure S4 The effects of the treatment with siRNA
specific for ORP150 on the expression of proteins
that reacted with CTD110.6 antibodies under glucose
deprivation. siRNAs targeting human ORP150 (NM_
001130991_stealth_455) RNA duplexes were purchased from
Invitrogen. The left panel shows an immunoblot for CTD110.6,
anti-ORP150, and anti-a-tubulin antibodies. The right panel shows a
quantitative analysis of reactivity with the ORP150 antibody,
normalized to the anti-a-tubulin signal for untreated samples in
high-glucose medium. The anti-ORP150 antibody reacted with
ORP150 and with GPR170 (mature form with glycosylation)
proteins. Error bars represent standard error from three experiments.
(TIF)
Figure S5 The effects of tunicamycin treatment on the
expression of proteins that reacted with CTD110.6
antibodies under glucose deprivation in HepG2 cells.
The immunoblots are shown for CTD110.6, anti-ORP150, anti-
Mac2BP, anti-CD98H, and anti-a-tubulin antibodies.
(TIF)
Figure S6 The effects of tunicamycin treatment on the
expression of proteins that reacted with CTD110.6
antibodies under glucose deprivation in Neuro-2 cells.
The immunoblots are shown for CTD110.6, anti-ORP150, and
anti-a-tubulin antibodies.
(TIF)
Table S1 Proteins that were induced by glucose depri-
vation of T24 cells and identified by LC/MS/MS
analysis. The probability score, P, is from a new scoring
algorithm in BioWorks that is based on the probability that the
peptide is a random match to the spectral data. Values of p,0.001
were considered statistically significant. The final score, Sf,
indicates how good the protein and peptide match is between
the experimental MS/MS data and the theoretical data. The Sf
score combines various scores into one final score. Values of Sf
.0.40 were considered statistically significant.
(TIF)
Table S2 The N-GlcNAc2-peptides from Mac2BP pro-
teins that were induced in T24 cells under glucose
deprivation and identified by LC/MS/MS analysis. The
probability score, P, is from a new scoring algorithm in BioWorks
that is based on the probability that the peptide is a random match
to the spectral data. The final score, Sf, indicates how good the
protein and peptide match is between the experimental MS/MS
data and the theoretical data. The Sf score combines various
scores into one final score. Each peptide score was derived using
the maximum amount of data available.
(TIF)
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